Astromech acquires Form Bio in $230 million all-stock deal

Nov 17, 2026
The Dallas AI company adds Form Bio's genetic medicine design tools; both companies came out of Colossal Biosciences.

Astromech, a Dallas AI company developing predictive models of biological change, has acquired Form Bio in an all-stock deal valued at $230 million. Astromech takes over Form Bio's intellectual property, selected contracts and assets, and its team.

The deal combines Astromech's models, which use data across species and evolutionary history to predict biological function, with Form Bio's AI tools for designing genetic medicines, optimising gene therapy vectors and their manufacturing, and checking genomic quality. The companies say the combination should help researchers catch quality problems at the design stage and could reduce the need for purification later in development.

Form Bio's tools support genetic medicine programs at Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies and Solid Biosciences, according to the company. In work with Cure Rare Disease on Duchenne muscular dystrophy, Form Bio says it raised full-genome content from 13% to 59% in less than 30 days by redesigning the promoter sequence.

Form Bio co-founder and former CEO Andrew Busey becomes Astromech's chief AI officer and head of technology. Both companies came out of Colossal Biosciences. Form Bio launched in 2022 and has raised more than $40 million, while Astromech, co-founded by George Church and Ben Lamm, has raised more than $60 million, according to the announcement.

We hope you enjoyed this article

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.